Literature DB >> 2223107

Current status of magnetic resonance imaging of the orbit.

R E Dorfman1, E M Spickler.   

Abstract

MR plays an important role in evaluating pathologic conditions that affect the orbit. MR appears to be superior to ultrasound and computed tomography in evaluation of intraocular tumors and fluid collections. In evaluation of noncalcified intraorbital tumors, MR can provide more information regarding orbital apex involvement and intracranial extension. Inflammatory lesions, particularly orbital pseudotumor, can be differentiated from metastatic disease based on differences in signal intensity providing greater specificity than CT. Specific prognostic information may be obtained regarding potentially treatable cases of Graves' disease. Using MR, vascular lesions of the orbit can be assessed for patency or thrombosis without use of intravenous contrast. Demonstration of secondary extension by para-orbital sinus tumors by MR is often helpful in evaluating involvement of the soft tissue structures of the orbit. Potential applications in evaluation of orbital trauma include characterization of orbital hematomas and orbital blow-out fractures.

Entities:  

Mesh:

Year:  1990        PMID: 2223107

Source DB:  PubMed          Journal:  Top Magn Reson Imaging        ISSN: 0899-3459


  4 in total

1.  Combined fat- and water-suppressed MR imaging of orbital tumors.

Authors:  A Jackson; S Sheppard; A C Johnson; D Annesley; R D Laitt; A Kassner
Journal:  AJNR Am J Neuroradiol       Date:  1999 Nov-Dec       Impact factor: 3.825

Review 2.  [Appearance of orbital diseases on MRI].

Authors:  I Kazi; R Felix; A-J Lemke
Journal:  Radiologe       Date:  2005-09       Impact factor: 0.635

Review 3.  Orbital sonography in children.

Authors:  F G Ramji; T L Slovis; J D Baker
Journal:  Pediatr Radiol       Date:  1996

4.  ORBITAL PSEUDOTUMOR CAN MIMIC GRAVES' OPHTHALMOPATHY.

Authors:  M Stanciu; F L Popa; I G Totoian; L G Bera
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Jul-Sep       Impact factor: 0.877

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.